ABCB1 and leukemia: What’s more, the MTT cytotoxicity assays showed that neratinib markedly sensitized primary leukemia blasts to doxurubin compared with the control group (P < 0.05), indicating neratinib may play a role in the reversal of ABCB1-mediated MDR phenotype [92].